HOME
>
臨床医学：内科
>
糖尿病
> 糖尿病網膜症のすべて

糖尿病網膜症のすべて

出版社：	中山書店
著者：	荒木栄一(編集主幹) 前川聡(専門編集)
発行日：	2012-02-20
分野：	臨床医学：内科 > 糖尿病
ISBN：	9784521733791
電子書籍版：	2012-02-20 （初版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

7,040 円(税込)

購入する

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

7,040 円(税込)

購入する

商品紹介

糖尿病３大合併症の一つである「網膜症」は途中失明のおそれがあり，患者のQOLを著しく損なうものであるため，本疾患の早期診断や継続的な経過観察において，内科医と眼科医の密接な連携が必要とされている。本書では，内科的治療の裏付けとなる大規模臨床研究の成果について簡潔に解説するとともに，眼科的な検査，診断，治療について，最新の情報をわかりやすく解説したものである。

目次

糖尿病網膜症のすべて

―目次―

1章　網膜症の概念・疫学
2章　網膜症の成因・病態生理・診断
3章　網膜症の検査法
4章　網膜症の臨床研究（内科的治療）
5章　網膜症の眼科治療
6章　その他の眼合併症

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章網膜症の概念・疫学

P.7 掲載の参考文献

1) http://www.aao.org/aao/

2) 田原義久ほか. 一般住民における糖尿病網膜症の有病率の調査-久山町研究. 臨眼 2000 ; 54 : 573-3.

3) Kuzuya T, et al. Prevalence of chronic complications in Japanese diabetic patients. Diabetes Res Clin Pract 1994 ; 24 (suppl) : S159-64.

4) Sone H, et al ; JD Study Group. Effects of lifestyle modifications on patients with type 2 diabetes : the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res 2002 ; 34 : 509-15.

5) 川崎良, 山下英俊. 地域住民を対象とした疫学研究 (3) : 糖尿病網膜症の危険因子-Wisconsin Epidemiologic Study of Diabetic Retinopathyからわかること. あたらしい眼科 2004 ; 21 : 441-7.

6) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.

7) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.

8) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.

9) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS38. UK Prospective Diabetes Study (UKPDS) Group. BMJ 1998 ; 317 : 703-13.

P.11 掲載の参考文献

1) Katsuki S, Hirota Y. Recent trends in incidence of cerebral hemorrhage and infarction in Japan. A report based on death rates, autopsy case and prospective study on cerebrovascular disease. Jpn Heart J 1966 ; 7 : 26-34.

2) Miyazaki M, et al ; Hisayama study. Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population : the Hisayama Study. Diabetologia 2004 ; 47 : 1411-5.

3) Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med 2003 ; 348 : 383-93.

P.16 掲載の参考文献

1) Kawasaki R, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population : the Funagata study. Ophthalmology 2008 ; 115 : 1376-81. 1381. e1-2.

2) Klein R, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991 ; 98 : 1128-34.

3) Mitchell P, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995 ; 102 : 1450-60.

4) Kawasaki R, et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with retinopathy in Japanese population : the Funagata study. Diabetes Obes Metab 2008 ; 10 : 514-5.

5) Kawasaki R, et al. Cardiovascular risk factors and retinal microvascular signs in an adult Japanese population : the Funagata Study. Ophthalmology 2006 ; 113 : 1378-84.

6) Tanabe Y, et al. Retinal arteriolar narrowing predicts 5-year risk of hypertension in Japanese people : the Funagata study. Microcirculation 2010 ; 17 : 94-102.

7) Kawasaki R, et al. Prevalence and associations of epiretinal membranes in an adult Japanese population : the Funagata study. Eye (Lond) 2009 ; 23 : 1045-51.

8) Kawasaki R, et al. Body mass index and vein occlusion. Ophthalmology 2008 ; 115 : 917-8.

9) Kawasaki R, et al. The metabolic syndrome and retinal microvascular signs in a Japanese population : the Funagata study. Br J Ophthalmol 2008 ; 92 : 161-6.

10) Alberti KG, et al. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006 ; 23 : 469-80.

2章網膜症の成因・病態生理・診断

P.21 掲載の参考文献

1) Funatsu H, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Opthalmol 2002 ; 86 : 311-5.

2) Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006 ; 26 : 275-8.

3) 佐藤幸裕. 各種stage分類. 樋田哲夫編. 眼科プラクティス 7 糖尿病眼合併症の診療指針. 文光堂 ; 2006. pp. 41-7.

4) 川崎良ほか. AAOによる糖尿病網膜症新分類について. あたらしい眼科 2003 ; 20 : 865-72.

P.26 掲載の参考文献

1) Akagi Y, et al. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci 1983 ; 24 : 1516-9.

2) Yamagishi S, et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 2002 ; 290 : 973-8.

3) Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol 1999 ; 14 : 233-9.

4) Kim SY, et al. Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas. Diabetes 2005 ; 54 : 1534-42.

5) Kita T, et al. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 2008 ; 105 : 17504-9.

P.33 掲載の参考文献

1) Kwiterovich KA, et al. Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study. Ophthalmology 1991 ; 98 : 1139-42.

2) Otani T, et al. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999 ; 127 : 688-93.

3) 岡野正. 糖尿病眼科診療-糖尿病網膜症と鑑別すべき疾患 (糖尿病網膜症以外の網膜血管障害). 眼科診療プラクティス 1995 ; 20 : 46-51.

P.38 掲載の参考文献

1) Davis MD, et al. A note on the O′Hare classification of the diabetic retinopathy. In : Godberg MF, Fine SL, eds. Symposium on the treatment of diabetic retinopathy. PHS Publ, No.1890, 1968. US Department of Health, Education and Welfare ; 1969.

2) 福田雅俊. 糖尿病網膜症の病期分類. 堀貞夫編. 眼科Mook 46 糖尿病と眼科診療. 金原出版 ; 1991. pp.117-25.

3) 船津英陽. IV 糖尿病網膜症の病期分類-4. ETDRS. 堀貞夫編. 糖尿病眼科学一日一課. メディカル葵出版 ; 1996. pp.70-3.

4) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991 ; 98 (5 Suppl) : 823-33.

5) http://www.aao.org/aao

P.42 掲載の参考文献

1) 北野滋彦. 糖尿病黄斑症. 池田恒彦ほか編. New Mook 眼科 8 糖尿病網膜症. 金原出版 ; 2005. pp. 84-90.

2) 高木均. 糖尿病黄斑浮腫の治療戦略.月刊糖尿病 2010 ; 2 : 80-8.

3) Lewis H, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992 ; 99 : 753-9.

P.51 掲載の参考文献

1) Cheung N, et al. Diabetic retinopathy. Lancet 2010 ; 376 : 124-36.

2) Liou GI, et al. Cannabidiol as a putative novel therapy for diabetic retinopathy : a postulated mechanism of action as an entry point for biomarker-guided clinical development. Curr Pharmacogenomics Person Med 2009 ; 7 : 215-22.

3) Guidry C, et al. Changes in IGF activities in human diabetic vitreous. Diabetes 2004 ; 53 : 2428-35.

4) Ohashi H, et al. Alterations in expression of angiopoietins and the Tie-2 receptor in the retina of streptozotocin induced diabetic rats. Mol Vis 2004 ; 10 : 608-17.

5) Watanabe D, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005 ; 353 : 782-92.

6) Chavakis E, Dimmeler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 2002 ; 22 : 887-93.

7) Yamagishi S, et al. Pigment epithelium-derived factor (PEDF) : its potential therapeutic implication in diabetic vascular complications. Curr Drug Targets 2008 ; 9 : 1025-9.

8) 島崎雅司, 工藤明. 歯根膜再生に機能するぺリオスチンの心筋梗塞修復, 癌被膜形成への寄与. 福岡医誌 2009 ; 100 : 67-74.

9) Li L, et al. Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblasts. Cardiovasc Res 2011 ; 91 : 80-9.

10) 谷口寿章. 導入編プロテオミクスとその解析技術. 最新プロテオミクス実験プロトコール. 秀潤社 ; 2003. pp. 7-12.

11) Teekakirikul P, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest 2010 ; 120 : 3520-9.

12) Simper D, et al. Comparative proteomics profiling reveals role of smooth muscle progenitors in extracellular matrix production. Arterioscler Thromb Vasc Biol 2010 ; 30 : 1325-32.

13) Yoshida S, et al. Increased expression of periostin in vitreous and fibrovascular membranes obtained from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2011 ; 52 : 5670-8.

14) Takada M, et al. Periostin, discovered by nano-flow liquid chromatography and mass spectrometry, is a novel marker of diabetic retinopathy. Biochem Biophys Res Commun 2010 ; 399 : 221-6.

P.56 掲載の参考文献

1) Inoguchi T, et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats : differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992 ; 89 : 11059-63.

2) Maeda Y, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 2010 ; 299 : F1328-38.

3) Mollnau H, et al. Effects of angiotensin II infusion on the expression and function of NAD (P) H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002 ; 90 : E58-65.

4) Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010 ; 106 : 1319-31.

5) Inoguchi T, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD (P) H oxidase in cultured vascular cells. Diabetes 2000 ; 49 : 1939-45.

6) Mustapha NM, et al. NADPH oxidase versus mitochondria-derived ROS in glucose-induced apoptosis of pericytes in early diabetic retinopathy. J Ophthalmol 2010. PMID : 20652059 [PubMed]

7) Zhang Q, et al. Activation of cytosolic phospholipase A2 downstream of the Srcphospholipase D1 (PLD1) -protein kinase Cγ (PKCγ) signaling axis is required for hypoxia-induced pathological retinal angiogenesis. J Biol Chem 2011 ; 286 : 22489-98.

8) Ishii H, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996 ; 272 : 728-31.

9) PKC-DRS2 Group, Aiello LP, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006 ; 113 : 2221-30.

10) Sheetz MJ, et al ; Mbdv Study Group. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy : results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina 2011 ; 31 : 1053-9.

11) Chaturvedi N, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes : randomised, placebo-controlled trials. Lancet 2008 ; 372 : 1394-402.

12) Chaturvedi N, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998 ; 351 : 28-31.

13) Sjolie AK, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomised placebo-controlled trial. Lancet 2008 ; 372 : 1385-93.

・Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010 ; 106 : 1319-31.

P.64 掲載の参考文献

1) Funatsu H, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002 ; 86 : 311-5.

2) Nagai N, et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005 ; 46 : 1078-84.

3) Nagai N, et al. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 2007 ; 48 : 4342-50.

4) Kurihara T, et al. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci 2006 ; 47 : 5545-52.

5) Kurihara T, et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008 ; 57 : 2191-8.

6) Chaturvedi N, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998 ; 351 : 28-31.

7) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 713-20.

8) Chaturvedi N, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes : randomised, placebo-controlled trials. Lancet 2008 ; 372 : 1394-402.

9) Sjolie AK, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomised placebo-controlled trial. Lancet 2008 ; 372 : 1385-93.

10) Mauer M, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009 ; 361 : 40-51.

P.71 掲載の参考文献

1) Ferrara N, et al. The biology of VEGF and its receptors. Nat Med 2003 ; 9 : 669-76.

2) Brownlee M. The pathobiology of diabetic complications : a unifying mechanism. Diabetes 2005 ; 54 : 1615-25.

3) Miyamoto K, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999 ; 96 : 10836-41.

4) Hammes HP, et al. Angiopoietin-2 causes pericyte dropout in the normal retina : evidence for involvement in diabetic retinopathy. Diabetes 2004 ; 53 : 1104-10.

5) Mitchell P, et al. The RESTORE study : ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011 ; 118 : 615-25.

6) Gaengel K, et al. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009 ; 29 : 630-8.

7) Aiello LP, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994 ; 331 : 1480-7.

8) Oh H, et al. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF) : a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA 2002 ; 99 : 383-8.

9) Oh H, et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999 ; 274 : 15732-9.

10) Watanabe D, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005 ; 353 : 782-92.

P.77 掲載の参考文献

1) Nishikawa T, et al. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003 ; 26 : 1507-12.

2) Hinokio Y, et al. Urinary excretion of 8-oxo-7, 8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 2002 ; 45 : 877-82.

3) Nishikawa T, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000 ; 404 : 787-90.

4) Araki E, et al. Oxidative stress : A cause and therapeutic target of diabetic complications. Journal of Diabetes Investigation 2010 ; 1 : 90-6.

5) Goto H, et al. Endothelial MnSOD overexpression prevents retinal VEGF expression in diabetic mice. Biochem Biophys Res Commun 2008 ; 366 : 814-20.

6) Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy : pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 2008 ; 9 : 315-27.

7) Lin J, et al. Effect of R- (+) -alpha-lipoic acid on experimental diabetic retinopathy. Diabetologia 2006 ; 49 : 1089-96.

8) Bursell SE, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999 ; 22 : 1245-51.

9) Millen AE, et al. Relation between intake of vitamins C and E and risk of diabetic retinopathy in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2004 ; 79 : 865-73.

P.84 掲載の参考文献

1) Leslie RD, Pyke DA. Diabetic retinopathy in identical twins. Diabetes 1982 ; 31 : 19-21.

2) Doria A. Genetics of diabetes complications. Curr Diab Rep 2010 ; 10 : 467-75.

3) Abhary S, et al. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009 ; 58 : 2137-47.

4) Cheung N, et al. Diabetic retinopathy. Lancet 2010 ; 376 : 124-36.

5) Ng DP. Human genetics of diabetic retinopathy : current perspectives. J Ophthalmol 2010 ; pii : 172593.

6) Fu YP, et al. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from starr county, Texas. J Ophthalmol 2010 ; pii : 861291.

7) Huang YC, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology 2011 ; 118 : 642-8.

8) Grassi MA, et al. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet 2011 ; 20 : 2472-81.

9) Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications. Prog Retin Eye Res 2008 ; 27 : 161-76.

10) Pirola L, et al. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010 ; 6 : 665-75.

3章網膜症の検査法

P.91 掲載の参考文献

1) Novotny HR, Alvis DL. A method of photographing fluorescence in circulating blood in the human retina. Circulation 1961 ; 24 : 82-6.

2) Flower RW, Hochheimer BF. A clinical technique and apparatus for simultaneous angiography of the separate retinal and choroidal circulations. Invest Ophthalmol 1973 ; 12 : 248-61.

3) 岡野正. 糖尿病性網膜症. 蛍光眼底造影による検索. 日眼会誌 1977 ; 81 : 69-134.

P.97 掲載の参考文献

1) Klein R, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984 ; 91 : 1464-74.

2) Otani T, et al. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999 ; 127 : 688-93.

3) Bolz M, et al. Optical coherence tomographic hyperreflective foci : a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009 ; 116 : 914-20.

4) Otani T, et al. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina 2010 ; 30 : 774-80.

P.101 掲載の参考文献

1) Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res 1998 ; 17 : 59-76.

2) Hiraiwa T, et al. Preoperative electroretinogram and postoperative visual outcome in patients with diabetic vitreous hemorrhage. Jpn J Ophthalmol 2003 ; 47 : 307-11.

・ Yonemura D et al. Electroretinogram in diabetic retinopathy. Arch Ophthalmol. 1962 ; 68 : 19-24.

・三宅養三. 黄斑部疾患の基礎と臨床. 黄斑部局所ERGの研究. 日眼会誌 1988 ; 92 : 1419-49.

4章網膜症の臨床研究 ( 内科的治療 )

P.110 掲載の参考文献

1) Zhang X, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010 ; 304 : 649-56.

2) NAVIGATOR Study Group ; McMurray JJ, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 ; 362 : 1477-90.

3) ACCORD Study Group ; ACCORD Eye Study Group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 ; 363 : 233-44.

4) Gallego PH, et al. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes : prospective cohort study. BMJ 2008 ; 337 : a918.

5) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.

6) Matthews DR, et al ; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus : UKPDS 69. Arch Ophthalmol 2004 ; 122 : 1631-40.

7) Keech AC, et al ; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study) : a randomised controlled trial. Lancet 2007 ; 370 : 1687-97.

P.118 掲載の参考文献

1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.

2) Kilpatrick ES, et al. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes : "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007 ; 30 : 707-12.

3) Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997 ; 46 : 1829-39.

4) Liew G, et al. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin 2009 ; 49 : 35-52.

P.124 掲載の参考文献

1) Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.

2) Kohner EM, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001 ; 18 : 178-84.

3) Kohner EM. Microvasucular disease : what does the UKPDS tell us about diabetic retinopathy. Diabet Med 2008 ; 25 (Suppl 2) : 20-4.

4) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study (UKPDS) Group. BMJ 1998 ; 317 : 703-13.

P.129 掲載の参考文献

1) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.

2) Shichiri M, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000 ; 23 (Suppl 2) : B21-9.

3) Wake N, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes : a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000 ; 48 : 201-10.

4) 七里元亮ほか. 熊本スタディを振り返って. 岡芳知編. 糖尿病学 2001. 診断と治療社 ; 2001. pp.1-11.

5) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. diabetes 1995 ; 44 : 968-83.

P.136 掲載の参考文献

1) 中江公裕ほか. 厚生労働科学研究研究費補助金難治性疾患克服研究事業「網脈絡膜萎縮・視神経萎縮に関する研究」平成17年度総括分担研究報告書. 2006.

2) Yau JWY, et al. for the Meta-analysis for eye diseases (META-EYE) study group. Global prevalence and major risk factors of diabetic retinopathy. Under review.

3) Wong TY, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes : three population-based cross-sectional studies. Lancet 2008 ; 371 : 736-43. Erratum in : Lancet 2008 ; 371 : 1838.

4) Kawasaki R, et al ; Japan Diabetes Complications Study Group. Incidence and progression of diabetic retinopathy in Japanese adult with type 2 diabetes : 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia 2011 ; 54 : 2288-94.

5) Wilkinson CP, et al ; Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003 ; 110 : 1677-82.

P.142 掲載の参考文献

1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.

2) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000 ; 342 : 381-9.

3) White NH, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus : 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008 ; 126 : 1707-15.

4) Genuth S, et al ; DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes control and complications trial and participants with type 1 diabetes. Diabetes 2005 ; 54 : 3103-11.

5) White NH, et al ; DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC : comparison of adults and adolescents. Diabetes 2010 ; 59 : 1244-53.

P.146 掲載の参考文献

1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.

2) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.

3) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.

4) Poulaki V, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 2002 ; 109 : 805-15.

5) Bursell SE, et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996 ; 37 : 886-97.

6) Grunwald JE, et al. Diabetic glycemic control and retinal blood flow. Diabetes 1990 ; 39 : 602-7.

7) Dahl-Jorgensen K, et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopahty in insulin dependent diabetes mellitus : the Oslo study. Br Med J (Clin Res Ed) 1985 ; 290 : 811-5.

・ Clermont AC, et al. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo : a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol 1997 ; 124 : 433-46.

P.152 掲載の参考文献

1) Chaturvedi N, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998 ; 351 : 28-31.

2) Larsen M, et al. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990 ; 228 : 505-9.

3) Chase HP, et al. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects : a two-year trial. Ann Ophthalmol 1993 ; 25 : 284-9.

4) Ravid M, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993 ; 118 : 577-81.

5) Mauer M, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009 ; 361 : 40-51.

6) Kuzuya T, et al. Prevalence of chronic complications in Japanese diabetic patients. Diabetes Res Clin Pract 1994 ; 24 (Suppl) : S159-64.

P.158 掲載の参考文献

・ Chaturvedi N, et al ; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes : randomised, placebo-controlled trials. Lancet 2008 ; 372 : 1394-402.

・ Sjolie AK, et al ; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomised placebo-controlled trial. Lancet 2008 ; 372 : 1385-93.

P.163 掲載の参考文献

1) Dodson PM, et al. Retinal vascular abnormalities in the hyperlipidaemias. Trans Ophthalmol Soc UK 1981 ; 101 : 17-21.

2) Miljanovic B, et al. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004 ; 53 : 2883-92.

3) Keech AC, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study) : arandomised controlled trial. Lancet 2007 ; 370 : 1687-97.

4) ACCORD study group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 ; 363 : 233-44.

5) Keech A, et al ; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 2005 ; 366 : 1849-61.

6) Hiukka A, et al. PPARα : an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010 ; 6 : 454-63.

P.168 掲載の参考文献

1) Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.

2) Aldington SJ, et al. Methodology for retinal photography and assessment of diabetic retinopathy : the EURODIAB IDDM complications study. Diabetologia 1995 ; 38 : 437-44.

3) Gaede P, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : the Steno type 2 randomised study. Lancet 1999 ; 353 : 617-22.

4) Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.

5) Sjolie AK, et al ; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomised placebo-controlled trial. Lancet 2008 ; 372 : 1385-93.

6) Araki S, et al. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008 ; 82 (Suppl 1) : S54-8.

P.174 掲載の参考文献

1) Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.

2) Keech AC, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study) : a randomised controlled trial. Lancet 2007 ; 370 : 1687-97.

3) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.

4) ACCORD Study Group ; ACCORD Eye Study Group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 ; 363 : 233-44.

5) ACCORD Study Group, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1575-85.

6) ACCORD Study Group, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1563-74.

7) ACCORD Study Group, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011 ; 364 : 818-28.

P.180 掲載の参考文献

1) Juutilainen A, et al. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 2007 ; 30 : 292-9.

2) Kramer CK, et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes : meta-analysis of observational studies. Diabetes Care 2011 ; 34 : 1238-44.

3) Gimeno-Orna JA, et al. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2009 ; 103 : 1364-7.

4) Klein R, et al. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 1999 ; 117 : 1487-95.

5) Tong PC, et al. Interactive effect of retinopathy and macroalbuminuria on all-cause mortality, cardiovascular and renal end points in Chinese patients with Type 2 diabetes mellitus. Diabet Med 2007 ; 24 : 741-6.

6) Janand-Delenne B, et al. Silent myocardial ischemia in patients with diabetes : who to screen. Diabetes Care 1999 ; 22 : 1396-400.

7) Gokcel A, et al. Silent coronary artery disease in patients with type 2 diabetes mellitus. Acta Diabetol 2003 ; 40 : 176-80.

8) Ohno T, et al. Detecting occult coronary artery disease followed by early coronary artery bypass surgery in patients with diabetic retinopathy : report from a diabetic retinocoronary clinic. J Thorac Cardiovasc Surg 2010 ; 139 : 92-7.

9) Wong TY, et al. Relation of retinopathy to coronary artery calcification : the multi-ethnic study of atherosclerosis. Am J Epidemiol 2008 ; 167 : 51-8.

10) Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009 ; 53 (5 Suppl) : S35-42.

P.185 掲載の参考文献

1) Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.

2) 曽根博仁ほか. 糖尿病の血管合併症のトータルケア-早期診断, そして予防へ. わが国の糖尿病血管合併症の実態. JDCSの結果より. 日内会誌 2009 ; 98 : 134-41.

3) Klein BE, et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes : Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med 2004 ; 164 : 1917-24.

4) Cheung N, et al. Diabetic retinopathy and the risk of coronary heart disease : the Atherosclerosis Risk in Communities Study. Diabetes Care 2007 ; 30 : 1742-6.

5) Kramer CK, et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes : meta-analysis of observational studies. Diabetes Care 2011 ; 34 : 1238-44.

6) American Diabetes Association. Standards of medical care in diabetes? 2008. Diabetes Care 2008 ; 31 (Suppl 1) : S12-54.

7) J-DOIT3. http://www.jdoit3.jp/

5章網膜症の眼科治療

P.193 掲載の参考文献

1) Miyazaki M, et al. Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population : the Hisayama Study. Diabetologia 2004 ; 47 : 1411-5.

2) Kawasaki R, et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with retinopathy in Japanese population : the Funagata study. Diabetes Obes Metab 2008 ; 10 : 514-5.

3) Lewis H, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992 ; 99 : 753-9.

4) Friberg TR, Karatza EC. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmology 1997 ; 104 : 2030-8.

5) Kadonosono K, et al. Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol 2000 ; 118 : 1116-8.

6) Enaida H, et al. Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina 2006 ; 26 : 631-6.

7) Mason JO 3rd, et al. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006 ; 142 : 685-8.

8) Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001 ; 132 : 425-7.

9) Haritoglou C, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006 ; 26 : 999-1005.

P.199 掲載の参考文献

1) Meyer-Schwickerath RE, Schott K. Diabetic retinopathy and photocoagulation. Am J Ophthalmol 1968 ; 66 : 597-603.

2) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991 ; 98 (5 Suppl) : 766-85.

3) 清水弘一. 分担研究報告書汎網膜光凝固治療による脈絡膜循環の変化と糖尿病血管新生緑内障のレーザー治療ならびに糖尿病網膜症の光凝固適応及び実施基準. 平成6年度糖尿病調査研究報告書. 厚生省 ; 1995. pp. 346-9.

4) Shimura M, et al. Posterior sub-Tenon's capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision. Ophthalmolgy 2006 ; 113 : 381-7.

5) Shimura M, et al. Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema. Br J Ophthalmol 2007 ; 91 : 449-54.

6) Tonello M, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008 ; 86 : 385-9.

7) Ehlers JP, et al. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008 ; 28 : 696-702.

8) Cho WB, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009 ; 29 : 516-22.

9) Blumenkranz MS, et al. Semiautomated patterned scanning laser for retinal photocoagulation. Retina 2006 ; 26 : 370-6.

10) Sanghvi C, et al. Initial experience with the Pascal photocoagulator : a pilot study of 75 procedures. Br J Ophthalmol 2008 ; 92 : 1061-4.

11) Wade EC, Blankenship GW. The effect of short versus long exposure times of argon laser panretinal photocoagulation on proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1990 ; 228 : 226-31.

12) Al-Hussainy S, et al. Pain response and follow-up of patients undergoing panretinal laser photocoagulation with reduced exposure times. Eye 2008 ; 22 : 96-9.

P.204 掲載の参考文献

1) Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988 ; 95 : 1307-20.

2) Sawada O, et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007 ; 125 : 1363-6.

P.213 掲載の参考文献

1) Aiello LP, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994 ; 331 : 1480-7.

2) Spaide RF, Fisher YL. Intravitreal bevacizmab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006 ; 26 : 275-8.

3) Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006 ; 26 : 699-700.

4) Yamaji H, et al. Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy. Arch Ophthalmol 2011 ; 129 : 106-7.

5) Matsuyama K, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010 ; 94 : 1215-8.

6) CATT Research Group, et al. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 2011 ; 364 : 1897-908.

P.216 掲載の参考文献

1) Avery RL, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006 ; 113 : 1695. e1-15.

2) Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006 ; 26 : 699-700.

3) Jiang Y, et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2009 ; 87 : 736-40.

P.222 掲載の参考文献

1) Funatsu H, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003 ; 110 : 1690-6.

2) Jonas JB, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003 ; 121 : 57-61.

3) Shimura M, et al. Visual outcome after intravitreal triamcinolone acetonide depends on optic coherence tomographic patterns in patients with diffuse diabetic macular edema. Retina 2011 ; 31 : 748-54.

4) Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010 ; 248 : 915-30.

5) Shimura M, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008 ; 145 : 854-61.

6) Guney S, et al. Dexamethasone prevents transport inhibition by hypoxia in rat lung and alveolar epithelial cells by stimulating activity and expression of Na+-K+-ATPase and epithelial Na+ channels. Am J Physiol Lung Cell Mol Physiol 2007 ; 293 : L1332-8.

7) Zhang X, et al. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008 ; 57 : 1026-33.

8) Shimura M, et al. Drug reflux during posterior subtenon infusion of triamcinolone acetonide in diffuse diabetic macular edema not only brings insufficient reduction but also causes elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2009 ; 247 : 907-12.

9) Shimura M, et al. Posterior sub-Tenon′s capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision. Ophthalmology 2006 ; 113 : 381-7.

10) Shimura M, et al. Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular edema. Br J Ophthalmol 2007 ; 91 : 449-54.

P.225 掲載の参考文献

1) 松本行弘ほか. 増殖糖尿病網膜症に対する初回経毛様体扁平部硝子体手術の術後経過-若年群と高齢群での比較. 眼科臨床紀要 2008 ; 1 : 115-21.

2) 山口真一郎ほか. 若年者増殖糖尿病網膜症に対する硝子体手術成績-10年前との比較. 眼科臨床医報 2006 ; 100 : 93-6.

P.228 掲載の参考文献

1) Phelps RL, et al. Changes in diabetic retinopathy during pregnancy. Correlations with regulation of hyperglycemia. Arch Ophthalmol 1986 ; 104 : 1806-10.

2) 木戸口裕. 妊娠と糖尿病性網膜症. 眼科 1991 ; 33 : 813-9.

3) Larinkari J, et al. Metabolic control and serum hormone levels in relation to retinopathy in diabetic pregnancy. Diabetologia 1982 ; 22 : 327-32.

4) 小川憲治ほか. 性ホルモン投与で増悪したと考えられる糖尿病網膜症. 眼紀 1993 ; 44 : 1338-42.

5) 北岡千晶ほか. 妊娠時における糖尿病網膜症とInsulin-like growth factor I (IGF-I). 糖尿病 1994 ; 37 : 641-8.

6) Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care 2000 ; 23 : 1084-91.

7) de Sereday MS, et al. Diagnostic criteria for gestational diabetes in relation to pregnancy outcome. J Diabetes Complications 2003 ; 17 : 115-9.

8) 船津英陽. 糖尿病網膜症の悪化因子, 抑制因子 (局所). 池田恒彦ほか編. NEW MOOK眼科 8. 糖尿病網膜症. 2005 ; 金原出版. pp.45-57.

9) 渥美義仁. 網膜症と妊娠. 樋田哲夫編. 眼科プラクティス 7. 糖尿病眼合併症の診療指針. 文光堂 ; 2006. pp.146-7.

10) 小川憲治. 妊娠と網膜症. 田野保雄編. 眼科診療プラクティス 20. 糖尿病眼科診療. 文光堂 ; 1995 pp.190-1.

6章その他の眼合併症

P.234 掲載の参考文献

1) Schultz RO, et al. Corneal endothelial changes in type I and type II diabetes mellitus. Am J Ophthalmol 1984 ; 98 : 401-10.

2) Schultz RO, et al. Diabetic keratopathy. Trans Am Ophthalmol Soc 1981 ; 79 : 180-99.

3) 大橋裕一. 糖尿病角膜症. 日眼会誌 1997 ; 101 : 105-10.

4) 細谷比左志. 糖尿病角膜症. 臨眼 1997 ; 51 : 45-8.

5) Hosotani, H et al. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol 1995 ; 119 : 288-94.

6) Dogru M, et al. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology 2001 ; 108 : 586-92.

7) Gobbels M, et al. Impairment of corneal epithelial barrier function in diabetics. Graefes Arch Clin Exp Ophthalmol 1989 ; 227 : 142-4.

8) Yokoi N, et al. Effects of aldose reductase inhibitor CT-112 on the corneal epithelial barrier of galactose-fed rats. Curr Eye Res 1997 ; 16 : 595-9.

P.240 掲載の参考文献

1) Brown GC, et al. Neovascular glaucoma. Etiologic considerations. Ophthalmology 1984 ; 91 : 315-20.

2) Iliev ME, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006 ; 142 : 1054-6.

3) Wakabayashi T, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008 ; 115 : 1571-80.

4) Takihara Y, et al. Combined Intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma 2011 ; 20 : 196-201.

5) Miki A, et al. Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Ophthalmol 2008 ; 92 : 1431-3.

6) Saito Y, et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol 2010 ; 88 : 96-102.

7) Sivak-Callcott JA, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001 ; 108 : 1767-76.

P.249 掲載の参考文献

1) Klein BE, et al. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities : the Beaver Dam Eye Study. Am J Ophthalmol 1998 ; 126 : 782-90.

2) Hennis A, et al. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. Arch Ophthalmol 2004 ; 122 : 525-30.

3) Oishi N, et al. Correlation between adult diabetic cataracts and red blood cell aldose reductase levels. Invest Ophthalmol Vis Sci 2006 ; 47 : 2061-4.

4) Kumamoto Y, et al. Epithelial cell density in cataractous lenses of patients with diabetes : association with erythrocyte aldose reductase. Exp Eye Res 2007 ; 85 : 393-9.

5) Suto C, et al. Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol 2006 ; 124 : 38-45.

6) Kim SJ, et al. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 2007 ; 114 : 881-9.

7) Takamura Y, et al. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009 ; 116 : 1151-7.

8) Morikubo S, et al. Corneal changes after small-incision cataract surgery in patients with diabetes mellitus. Arch Ophthalmol 2004 ; 122 : 966-9.

9) Kato S, et al. Anterior capsular contraction after cataract surgery in eyes of diabetic patients. Br J Ophthalmol 2001 ; 85 : 21-3.

10) Hayashi K, et al. Posterior capsule opacification after cataract surgery in patients with diabetes mellitus. Am J Ophthalmol 2002 ; 134 : 10-6.

書評

書評を投稿する

最近チェックした商品履歴

Loading...